Vaccine description | |
---|---|
Target | SARS-CoV-2 |
Vaccine type | mRNA |
Clinical data | |
Trade names | Spikevax[1] |
Routes of administration | Intramuscular |
mRNA-1283 is a COVID-19 vaccine candidate developed by Moderna.[2][3]
An expectation, or hope seems to be that this "next generation" vaccine can be stored at regular refrigerator temperature (2-5 °C). [4]
In December, Moderna started a clinical trial which would evaluate the vaccine's ability to provoke an immune response and its safety.[5] As of September 2022, the trial is in Phase 2 [6]
An expectation, or hope seems to be that this "next generation" vaccine can be stored at regular refrigerator temperature. [4]
Development | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Classes | |||||||||||
Administration | |||||||||||
Vaccines |
| ||||||||||
Inventors/ researchers | |||||||||||
Controversy | |||||||||||
Related | |||||||||||
|